Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:SELB
- CUSIP: N/A
- Web: selectabio.com/
- 50 Day Moving Avg: $17.67
- 200 Day Moving Avg: $14.78
- 52 Week Range: $10.26 - $28.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.86
- P/E Growth: 0.00
- Net Margins: -11,046.71%
- Return on Equity: -126.40%
- Return on Assets: -74.41%
- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 5.37%
- Quick Ratio: 5.37%
- Average Volume: 110,729 shs.
Frequently Asked Questions for Selecta Biosciences (NASDAQ:SELB)
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc (NASDAQ:SELB) issued its earnings results on Thursday, May, 11th. The company reported ($0.82) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.22) by $0.40. The business earned $0.14 million during the quarter. Selecta Biosciences had a negative return on equity of 126.40% and a negative net margin of 11,046.71%. View Selecta Biosciences' Earnings History.
Where is Selecta Biosciences' stock going? Where will Selecta Biosciences' stock price be in 2017?
3 analysts have issued twelve-month target prices for Selecta Biosciences' stock. Their forecasts range from $25.00 to $32.00. On average, they anticipate Selecta Biosciences' share price to reach $28.33 in the next year. View Analyst Ratings for Selecta Biosciences.
What are analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (7/12/2017)
- 2. Needham & Company LLC analysts commented, "Selecta presented initial Phase II multi-dose data for SEL-212 on its 4Q16 earnings call. We believe this early data is very encouraging as a clinically active monthly dose appears to have been reached. Dosing continues with 2 additional cohorts. The next update is expected at a conference in June. We remain buyers of SELB as we believe they have both a promising clinical candidate in SEL-212 and a broadly applicable platform to induce tolerance to anti-drug antibodies." (3/28/2017)
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE) and Agios Pharmaceuticals (AGIO).
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Werner Cautreels Ph.D., Chairman of the Board, President, Chief Executive Officer
- Omid Farokhzad M.D., Co-Founder, Director
- David Siewers, Chief Financial Officer, Treasurer
- Lloyd Johnston Ph.D., Chief Operating Officer, Senior Vice President - Research & development
- Takashi Kei Kishimoto Ph.D., Chief Scientific Officer
- David Abraham J.D., Chief Compliance Officer, General Counsel, Corporate Secretary
- Peter Keller, Chief Business Officer
- Dmitry Ovchinnikov, Managing Director, SelectaRUS, LLC
- Earl Sands M.D., Chief Medical Officer
- Carl L. Gordon Ph.D., Director
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
Who owns Selecta Biosciences stock?
Selecta Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hamilton Lane Advisors LLC (0.00%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Edwin M Kania, Jr, Lloyd P Johnston, Nanodimension Management Ltd, Peter Keller, Takashi Kei Kishimoto and Timothy A Springer. View Institutional Ownership Trends for Selecta Biosciences.
Who bought Selecta Biosciences stock? Who is buying Selecta Biosciences stock?
Selecta Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Nanodimension Management Ltd and Timothy A Springer. View Insider Buying and Selling for Selecta Biosciences.
How do I buy Selecta Biosciences stock?
Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Selecta Biosciences stock can currently be purchased for approximately $18.24.
Consensus Ratings for Selecta Biosciences (NASDAQ:SELB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$28.33 (55.34% upside)|
Analysts' Ratings History for Selecta Biosciences (NASDAQ:SELB)
(Data available from 7/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/13/2017||Canaccord Genuity||Set Price Target||Buy||$25.00||Low|
|3/28/2017||Needham & Company LLC||Reiterated Rating||Buy||$28.00||High|
|12/8/2016||Stifel Nicolaus||Reiterated Rating||Buy||$23.00 -> $32.00||N/A|
Earnings History for Selecta Biosciences (NASDAQ:SELB)Earnings History by Quarter for Selecta Biosciences (NASDAQ SELB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/11/2017||Q1 2017||($1.22)||($0.82)||$0.14 million||View||N/A|
|3/27/2017||12/31/2016||($0.25)||($0.77)||$15.00 million||$2.93 million||View||N/A|
Earnings Estimates for Selecta Biosciences (NASDAQ:SELB)
Current Year EPS Consensus Estimate: $-3.34 EPS
Next Year EPS Consensus Estimate: $-2.66 EPS
Dividend History for Selecta Biosciences (NASDAQ:SELB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Selecta Biosciences (NASDAQ:SELB)
Institutional Ownership Percentage: 45.60%Insider Trades by Quarter for Selecta Biosciences (NASDAQ:SELB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/3/2017||Lloyd P Johnston||COO||Sell||5,959||$19.10||$113,816.90|| |
|6/30/2017||David Siewers||CFO||Sell||7,420||$20.00||$148,400.00|| |
|6/29/2017||David Siewers||CFO||Sell||9,652||$20.00||$193,040.00|| |
|6/27/2017||Peter Keller||Insider||Sell||4,595||$19.30||$88,683.50|| |
|6/27/2017||Timothy A Springer||Director||Buy||338,791||$17.71||$5,999,988.61|| |
|6/26/2017||David Siewers||CFO||Sell||6,886||$20.00||$137,720.00|| |
|6/15/2017||Lloyd P Johnston||COO||Sell||20,512||$17.00||$348,704.00|| |
|6/1/2017||Timothy A Springer||Director||Buy||518||$13.75||$7,122.50|| |
|5/18/2017||Timothy A Springer||Director||Buy||16,104||$14.00||$225,456.00|| |
|5/16/2017||Edwin M. Kania, Jr.||Director||Sell||266,795||$14.00||$3,735,130.00|| |
|4/17/2017||Lloyd P Johnston||COO||Sell||13,205||$13.95||$184,209.75|| |
|12/28/2016||Takashi Kei Kishimoto||Insider||Sell||10,000||$17.55||$175,500.00|| |
|12/21/2016||David Abraham||Insider||Sell||14,844||$18.00||$267,192.00|| |
|12/19/2016||Peter Keller||Insider||Sell||4,723||$18.58||$87,753.34|| |
|6/27/2016||Amir Nashat||Director||Buy||150,000||$14.00||$2,100,000.00|| |
|6/27/2016||Nanodimension Management Ltd||Major Shareholder||Buy||385,000||$14.00||$5,390,000.00|| |
Headline Trends for Selecta Biosciences (NASDAQ:SELB)
Latest Headlines for Selecta Biosciences (NASDAQ:SELB)
|Selecta Biosciences, Inc. (NASDAQ:SELB) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 25 at 8:40 PM
|Selecta Biosciences, Inc. (NASDAQ:SELB) Upgraded to Hold by Zacks Investment Research|
www.americanbankingnews.com - July 12 at 5:28 PM
|Selecta Biosciences, Inc. (NASDAQ:SELB) COO Lloyd P. Johnston Sells 5,959 Shares|
www.americanbankingnews.com - July 6 at 8:04 PM
|-$0.86 Earnings Per Share Expected for Selecta Biosciences, Inc. (NASDAQ:SELB) This Quarter|
www.americanbankingnews.com - July 6 at 6:20 PM
|Insider Selling: Selecta Biosciences, Inc. (NASDAQ:SELB) CFO Sells 7,420 Shares of Stock|
www.americanbankingnews.com - July 5 at 7:44 PM
|ValuEngine Upgrades Selecta Biosciences, Inc. (SELB) to "Hold"|
www.americanbankingnews.com - July 1 at 9:28 AM
|Selecta Biosciences, Inc. (NASDAQ:SELB) CFO David Siewers Sells 9,652 Shares|
www.americanbankingnews.com - June 30 at 7:29 PM
|Selecta Biosciences, Inc. (NASDAQ:SELB) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - June 30 at 5:08 PM
|Insider Selling: Selecta Biosciences, Inc. (SELB) Insider Sells 4,595 Shares of Stock|
www.americanbankingnews.com - June 28 at 7:41 PM
|David Siewers Sells 6,886 Shares of Selecta Biosciences, Inc. (SELB) Stock|
www.americanbankingnews.com - June 28 at 7:40 PM
|Timothy A. Springer Purchases 338,791 Shares of Selecta Biosciences, Inc. (SELB) Stock|
www.americanbankingnews.com - June 28 at 7:20 PM
|Selecta Biosciences (SELB) Reports $50M Private Placement of Common Stock|
www.streetinsider.com - June 27 at 8:13 AM
|Selecta Biosciences Announces $50 Million Private Placement|
finance.yahoo.com - June 27 at 8:13 AM
| Analysts Set $26.67 Price Target for Selecta Biosciences, Inc. (SELB)|
www.americanbankingnews.com - June 22 at 10:46 PM
|Selecta Biosciences, Inc. (SELB) COO Lloyd P. Johnston Sells 20,512 Shares|
www.americanbankingnews.com - June 19 at 7:35 PM
|Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors|
finance.yahoo.com - June 19 at 9:45 AM
|Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher|
finance.yahoo.com - June 16 at 4:07 PM
|Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout|
finance.yahoo.com - June 15 at 4:38 PM
|Selecta Biosciences, Inc. (SELB) Expected to Post Earnings of -$0.86 Per Share|
www.americanbankingnews.com - June 12 at 6:16 PM
|Selecta Biosciences Announces Upcoming Clinical Presentations|
finance.yahoo.com - June 6 at 10:14 PM
|ETFs with exposure to Selecta Biosciences, Inc. : June 6, 2017|
finance.yahoo.com - June 6 at 10:14 PM
|Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017|
finance.yahoo.com - June 3 at 12:07 AM
|Zacks: Analysts Set $26.67 Price Target for Selecta Biosciences Inc (SELB)|
www.americanbankingnews.com - June 2 at 7:34 AM
|Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 7, 2017|
finance.yahoo.com - May 31 at 12:33 PM
|Selecta Biosciences Inc (SELB) Director Buys $225,456.00 in Stock|
www.americanbankingnews.com - May 19 at 7:58 PM
|Insider Selling: Selecta Biosciences Inc (SELB) Director Sells 266,795 Shares of Stock|
www.americanbankingnews.com - May 16 at 7:14 PM
|-$0.86 EPS Expected for Selecta Biosciences Inc (SELB) This Quarter|
www.americanbankingnews.com - May 16 at 9:20 AM
| Selecta Biosciences Inc (SELB) Receives Average Rating of "Strong Buy" from Analysts|
www.americanbankingnews.com - May 16 at 8:06 AM
|Edited Transcript of SELB earnings conference call or presentation 11-May-17 9:00pm GMT|
finance.yahoo.com - May 15 at 9:26 AM
|Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)|
finance.yahoo.com - May 15 at 9:26 AM
|Selecta Biosciences Inc (SELB) PT Set at $25.00 by Canaccord Genuity|
www.americanbankingnews.com - May 15 at 12:34 AM
|Selecta Biosciences Inc (SELB) Posts Quarterly Earnings Results, Beats Expectations By $0.40 EPS|
www.americanbankingnews.com - May 12 at 12:14 PM
|Selecta Biosciences (SELB) Commences Dosing in Phase 1 Trial of Nicotine Vaccine for Smoking Cessation|
www.streetinsider.com - May 12 at 1:14 AM
|Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention|
finance.yahoo.com - May 11 at 8:14 PM
|Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - May 11 at 8:14 PM
|Selecta Biosciences to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017|
finance.yahoo.com - May 4 at 11:14 AM
|Zacks: Selecta Biosciences Inc (SELB) Given $26.67 Consensus Target Price by Analysts|
www.americanbankingnews.com - May 4 at 12:12 AM
|Ready for Launch: Selecta Biosciences Inc. Jumps as Much as 16%|
www.fool.com - May 2 at 5:22 PM
|Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers|
finance.yahoo.com - May 2 at 9:33 AM
|Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy|
finance.yahoo.com - May 1 at 8:46 AM
|ETFs with exposure to Selecta Biosciences, Inc. : April 26, 2017|
finance.yahoo.com - April 26 at 4:15 PM
|Selecta Biosciences to Present at Two Upcoming Investor Conferences in May|
finance.yahoo.com - April 26 at 9:24 AM
|Selecta Biosciences Inc (SELB) Short Interest Update|
www.americanbankingnews.com - April 26 at 12:40 AM
|Selecta Biosciences Inc (SELB) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - April 20 at 8:23 PM
|Insider Selling: Selecta Biosciences Inc (SELB) COO Sells 13,205 Shares of Stock|
www.americanbankingnews.com - April 18 at 7:55 PM
|Selecta Biosciences Inc (SELB) Downgraded by Zacks Investment Research to Sell|
www.americanbankingnews.com - April 8 at 7:25 AM
|ETFs with exposure to Selecta Biosciences, Inc. : April 5, 2017|
finance.yahoo.com - April 7 at 12:30 PM
|SELECTA BIOSCIENCES INC Financials|
finance.yahoo.com - March 31 at 7:58 PM
|Edited Transcript of SELB earnings conference call or presentation 27-Mar-17 9:00pm GMT|
finance.yahoo.com - March 28 at 7:35 PM
|Selecta Biosciences Inc (SELB) Earns Buy Rating from Needham & Company LLC|
www.americanbankingnews.com - March 28 at 9:50 AM
Selecta Biosciences (SELB) Chart for Wednesday, July, 26, 2017